轻型颅脑创伤生物标志物的研究进展
[摘要] 轻型颅脑创伤（mTBI）发生率居高不下，成为世界性公共健康问题。临床上迫切需要更好的实践指南以规范mTBI诊疗，进而为mTBI患者提供安全返回工作岗位的时间表。影像学检查在mTBI诊断方面尚不敏感，开发一套能够反映mTBI潜在病理生理学的生物标志物将有助于mTBI的临床诊断和预后评估。本文基于mTBI的病理解剖及病理生理学，系统阐述血脑屏障破坏、轴索损伤、神经炎性反应及基因生物标志物研究进展，旨在发现一些可在临床上推广的生物标志物，推动mTBI的客观诊断及个性化治疗。
[关键词] 轻型颅脑创伤；生物标志物；病理学；诊断
[中图分类号] R446 [文献标识码] A [文章编号] 1673-7210（2018）09（c）-0021-05
[Abstract] The incidence of mild traumatic brain injury （mTBI） has remained high and has become a worldwide public health problem. There is a pressing need for better practice guidelines in clinic to standardize mTBI clinics， thereby providing mTBI patients with a timetable to return to work safe. Imaging studies are not yet sensitive to the diagnosis of mTBI， and the development of a set of biomarkers that can reflect the underlying pathophysiology of mTBI， that will contribute to clinical diagnosis and prognostic of mTBI. Based on the pathological anatomy and pathophysiology of mTBI， this article systematically elaborates the advancements of blood-brain barrier disruption， axonal injury， neuroinflammation， and gene biomarkers， in order to discover some promising biomarkers that are availible in clinic and promote mTBI objective diagnosis and personalized treatment.
[Key words] Mild traumatic brain injury； Biomarkers； Pathology； Diagnosis
輕型颅脑创伤（mild traumatic brain injury，mTBI）是世界性的公共健康问题，全球每年新增5200万～5600万mTBI患者[1]。mTBI通常影响患者执行、学习和记忆功能[2]。若在第一次mTBI未处理之前再次发生mTBI将使损伤作用加重，导致认知功能明显减退、需要更长恢复时间等[3]。影像学检查无法在事故现...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
